Comparison Bioavailability Study of Quinine Sulfate in Chocolate Pudding
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Tracking Information | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| First Received Date ICMJE | December 8, 2008 | ||||||||
| Last Updated Date | August 22, 2012 | ||||||||
| Start Date ICMJE | July 2007 | ||||||||
| Primary Completion Date | August 2007 (final data collection date for primary outcome measure) | ||||||||
| Current Primary Outcome Measures ICMJE |
|
||||||||
| Original Primary Outcome Measures ICMJE |
Pharmacokinetic parameters for plasma quinine including Cmax, Tmax, Kel , T 1/2, AUC 0-t, AUCinf, AUC/AUCinf will be calculated to determine whether the 2 methods of administration are bioequivalent. [ Time Frame: 2 days ] [ Designated as safety issue: No ] | ||||||||
| Change History | Complete list of historical versions of study NCT00806078 on ClinicalTrials.gov Archive Site | ||||||||
| Current Secondary Outcome Measures ICMJE | Not Provided | ||||||||
| Original Secondary Outcome Measures ICMJE |
Adverse events including EKG changes from baseline, that occur after dosing will be recorded and reported to CRF with severity and judgement of likely causality by the investigator. [ Time Frame: 2 days ] [ Designated as safety issue: No ] | ||||||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||||||
| Descriptive Information | |||||||||
| Brief Title ICMJE | Comparison Bioavailability Study of Quinine Sulfate in Chocolate Pudding | ||||||||
| Official Title ICMJE | A Comparison of the Bioavailability of Quinine Sulfate Capsules Following a 648 mg Dose When Mixed in Chocolate Pudding Relative to That With Intact Capsules in Healthy Adults Under Fasting Conditions | ||||||||
| Brief Summary | This is an open label randomized single dose two-way crossover study to compare the bioavailability of a single oral dose of quinine sulfate 648 mg(2 x 324 mg) when mixed with 120 ml of chocolate pudding relative to the same dose given as two intact capsules. |
||||||||
| Detailed Description | Prior studies have shown that intact quinine sulfate capsules can be taken without regard for food. This is an open label randomized single dose two-way crossover study to compare the bioavailability of a single oral dose of quinine sulfate 648mg(2 x 324 mg capsules) when opened and mixed with 120 ml of chocolate pudding relative to the same dose given as two intact capsules. Eighteen healthy adult subjects will be enrolled. Following a fast of at least 10 hours subjects will be randomized to receive either 648 mg of quinine sulfate as the intact capsules or opened mixed in 120ml of chocolate pudding. Following a washout period of at least 7 days all subjects will be given the alternate dose under similar conditions. Following each dose, blood samples will be collected at times sufficient to determine the difference in bioavailability (if any) between the two methods of drug administration. In addition patients will be monitored for any adverse events including Electrocardiogram (EKG) changes (at baseline and 4 hours after each dose). |
||||||||
| Study Type ICMJE | Interventional | ||||||||
| Study Phase | Phase 1 | ||||||||
| Study Design ICMJE | Allocation: Randomized Endpoint Classification: Bio-equivalence Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Basic Science |
||||||||
| Condition ICMJE | Healthy | ||||||||
| Intervention ICMJE | Drug: quinine sulfate
2 x 324 mg capsules (648 mg)
Other Name: Qualaquin |
||||||||
| Study Arm (s) |
|
||||||||
| Publications * | Not Provided | ||||||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
| Recruitment Information | |||||||||
| Recruitment Status ICMJE | Completed | ||||||||
| Enrollment ICMJE | 18 | ||||||||
| Completion Date | August 2007 | ||||||||
| Primary Completion Date | August 2007 (final data collection date for primary outcome measure) | ||||||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
PR interval on EKG >200 msec at screening or prior to dose in either dosing period
|
||||||||
| Gender | Both | ||||||||
| Ages | 18 Years to 50 Years | ||||||||
| Accepts Healthy Volunteers | Yes | ||||||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||||
| Location Countries ICMJE | Canada | ||||||||
| Administrative Information | |||||||||
| NCT Number ICMJE | NCT00806078 | ||||||||
| Other Study ID Numbers ICMJE | MPC-001-07-1004 | ||||||||
| Has Data Monitoring Committee | No | ||||||||
| Responsible Party | Mutual Pharmaceutical Company, Inc. | ||||||||
| Study Sponsor ICMJE | Mutual Pharmaceutical Company, Inc. | ||||||||
| Collaborators ICMJE | Not Provided | ||||||||
| Investigators ICMJE |
|
||||||||
| Information Provided By | Mutual Pharmaceutical Company, Inc. | ||||||||
| Verification Date | August 2012 | ||||||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||||||